Bafna Pharmaceuticals Limited (BAFNAPH) AI Stock Analysis

• Market Cap: ₹2.41B
• Dividend Yield: N/A
• Average Volume (3M): 6.09K
• Price to Earnings (P/E): 30.0
• Beta (1Y): 0.44
• Revenue Growth: 2.36%
• EPS Growth: 2924.94%
• Country: IN
• Employees: 363
• Sector: Healthcare
• Sector Strength: 51
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.43
• Shares Outstanding: 23,656,336
• 10 Day Avg. Volume: 8,695
• 30 Day Avg. Volume: 6,090
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹119.00
• Price Target Upside: 13.71% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 65 Neutral
• Price Target: ₹119.00 ▲(13.71% Upside)

Bafna Pharmaceuticals Limited's stock score is primarily driven by its strong financial performance, despite challenges in profitability and cash flow stability. The technical analysis indicates bullish momentum, but overbought signals suggest caution. The valuation is less attractive due to a high P/E ratio and lack of dividend yield.

Bafna Pharmaceuticals Limited Business Overview & Revenue Model

Company Description

Bafna Pharmaceuticals Limited (BAFNAPH) is an Indian pharmaceutical company engaged in the development, manufacturing, and marketing of pharmaceutical formulations. The company operates in the pharmaceutical sector, focusing primarily on niche therapeutic areas and generic drug manufacturing. Bafna Pharmaceuticals serves both domestic and international markets, offering a wide range of products that include tablets, capsules, and liquid formulations to meet various healthcare needs.

How the Company Makes Money

Bafna Pharmaceuticals Limited generates revenue through the sale of its pharmaceutical products both in India and overseas. The company's revenue streams primarily include domestic sales of generic drugs and exports to international markets, where they have developed significant market presence over the years. Their product portfolio spans multiple therapeutic categories, allowing them to cater to a diverse customer base. Strategic partnerships with international distributors and healthcare providers also play a crucial role in expanding their market reach and enhancing their sales. Furthermore, the company may engage in contract manufacturing for other pharmaceutical firms, providing additional revenue opportunities.

Bafna Pharmaceuticals Limited Financial Statement Overview

Summary

Bafna Pharmaceuticals Limited demonstrates strong revenue growth and a robust equity position, contributing to its overall financial health. However, declining profitability margins, increased leverage, and volatile cash flows pose challenges. The company should focus on stabilizing profitability and cash flows to ensure sustainable financial performance in the future.

Income Statement

Bafna Pharmaceuticals Limited has shown impressive revenue growth from 2020 to 2025, with a remarkable increase in total revenue. However, the company has experienced declining gross profit and net income in the most recent year compared to the prior year. The net profit margin and EBIT margin have also compressed, indicating pressure on profitability. Despite these challenges, the historical growth trajectory supports a positive outlook.

Balance Sheet

The company's balance sheet shows a stable equity base with positive growth over the years. The debt-to-equity ratio remains moderate, suggesting manageable leverage. However, a decrease in equity ratio suggests a slight increase in leverage risk. Overall, the company maintains a sound financial position, but attention is needed on debt levels.

Cash Flow

The cash flow analysis reveals fluctuating free cash flow with a recent negative trend, indicating potential liquidity challenges. Although operating cash flow has recovered in recent years, the free cash flow remains volatile with a negative growth rate. The company needs to focus on enhancing cash flow stability to support operations and investments.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2020
Income Statement
Total Revenue	1.46B	1.52B	1.15B	851.40M	424.73M
Gross Profit	168.77M	452.15M	387.56M	336.00M	19.29M
EBITDA	117.73M	146.34M	189.88M	112.34M	13.90M
Net Income	41.52M	73.48M	113.38M	52.16M	-18.78M
Balance Sheet
Total Assets	1.53B	1.48B	1.30B	901.45M	710.61M
Cash, Cash Equivalents and Short-Term Investments	34.33M	13.96M	78.09M	194.00K	81.85M
Total Debt	281.99M	243.89M	229.24M	110.59M	30.18M
Total Liabilities	663.58M	668.43M	561.29M	281.81M	201.16M
Stockholders Equity	848.07M	808.39M	734.55M	619.64M	509.45M
Cash Flow
Free Cash Flow	-23.31M	-63.63M	-32.66M	21.87M	-356.97M
Operating Cash Flow	195.29M	94.85M	49.52M	97.28M	-342.68M
Investing Cash Flow	-213.02M	-150.54M	-74.93M	-65.44M	327.75M
Financing Cash Flow	38.09M	-8.45M	101.77M	-48.15M	72.71M

Bafna Pharmaceuticals Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 104.65
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BAFNAPH, the sentiment is Positive. The current price of 104.65 is above the 20-day moving average (MA) of 96.55, above the 50-day MA of 89.77, and above the 200-day MA of 81.11, indicating a bullish trend. The MACD of 3.81 indicates Positive momentum. The RSI at 60.41 is Neutral, neither overbought nor oversold. The STOCH value of 42.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BAFNAPH.

Bafna Pharmaceuticals Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BAFNAPH	65 Neutral	₹2.41B	29.95		―	2.36%	2924.94%
AAREYDRUGS	60 Neutral	₹1.70B	47.43		―	-4.74%	-41.53%
MANGALAM	58 Neutral	₹1.17B	19.78		―	-16.39%	-409.96%
BALPHARMA	55 Neutral	₹1.39B	19.47		1.35%	-14.16%	-6.46%
Sector *	51 Neutral	$7.86B	-0.26	-41.41%	2.22%	22.87%	-2.01%
ALPA	―	₹1.99B	7.67		―	―	―
KREBSBIO	39 Underperform	₹1.57B	―		―	-31.91%	-38.46%

Bafna Pharmaceuticals Limited Corporate Events

Bafna Pharmaceuticals Completes Sale of Chennai Manufacturing Unit

Bafna Pharmaceuticals Limited has completed the sale of its manufacturing unit located in Madhavaram, Chennai, to Navron Pharma Private Limited. This transaction, finalized on June 30, 2025, was approved by the company’s Board of Directors and shareholders, and it marks a strategic move to streamline operations. The sale, which is not a related party transaction, involved a consideration of Rs. 1,45,13,260 and represents a minor portion of the company’s revenue and net worth, contributing 0.08% and 1.55% respectively. This move is expected to impact the company’s operational focus and potentially enhance its financial positioning.

Bafna Pharmaceuticals Submits Annual SEBI Disclosure

Bafna Pharmaceuticals Limited has submitted its annual disclosure under Regulation 31(4) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, to the stock exchanges. This disclosure, received from the company’s promoters, is a regulatory requirement that provides transparency about substantial share acquisitions and takeovers, ensuring stakeholders are informed about the company’s shareholding structure.

Bafna Pharmaceuticals Announces Board and Committee Restructuring

Bafna Pharmaceuticals Limited announced the retirement of Mr. Palamadai Krishnan Sundaresan as an Independent Director, effective June 24, 2025. This change led to the reconstitution of the Audit and Nomination & Remuneration Committees, ensuring continued compliance with regulatory requirements. The new committee members include Mr. Navin Kumar as Chairman of the Audit Committee and Mrs. Ravichandran Chitra as Chairperson of the Nomination and Remuneration Committee. Despite the changes, the board and its committees remain in compliance with applicable laws, maintaining stability in the company’s governance structure.

Bafna Pharmaceuticals Announces Board and Committee Restructuring

Bafna Pharmaceuticals Limited announced the retirement of Mr. Palamadai Krishnan Sundaresan as an Independent Director, effective June 24, 2025. This change also affects his roles as Chairman of the Audit Committee and Member of the Nomination & Remuneration Committee. The company has reconstituted these committees with new appointments, ensuring continued compliance with applicable laws. This transition reflects Bafna Pharmaceuticals’ adaptability and commitment to maintaining strong governance structures.